Aaron Gerds MD, MS

Medical Director @caseccc CRO | Associ Prof | Cleveland Clinic Taussig Cancer Institute | EIC @ASHClinicalNews | Opinions here are mine

[Aaron Gerds MD, MS @AaronGerds]

"Of course, this would be in violation of some rules of time travel – right, Biff?"

Knowing Nothing Has Meant Everything https://t.co/CUPDg1eV7T

[ASH Clinical News @ASHClinicalNews]

#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: https://t.co/NETwE0aPOP

[Aaron Gerds MD, MS @AaronGerds]

Exciting stuff happening here at the @ASH_hematology Annual Meeting! #mpnsm @ClevelandClinic @CleClinicNews #ASH25

[ASH Clinical News @ASHClinicalNews]

Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging.

[Aaron Gerds MD, MS @AaronGerds]

Stop by our poster on Sunday! Paper No: 4340 Using a medically trained LLM-based end-to-end system in automating patient eligibility screening across a health system for A phase 3 study evaluating the safety of givinostat in patients with PV. #ASH25 @ClevelandClinic

[OncLive.com @OncLive]

Ahead of #ASH25, @AaronGerds, @n_gangat, and John O. Mascarenhas, MD, weigh in on the most anticipated presentations in #MPN.🩸

Sign up below to read their insights👇& ensure you're up to speed on the data poised to shape practice. 📊 @ASH_hematology

🔐https://t.co/Jt7wHXMVtx

[Aaron Gerds MD, MS @AaronGerds]

https://t.co/AMGLDKOonf

[Aaron Gerds MD, MS @AaronGerds]

@MikkaelSekeres @ASH_hematology @SylvesterCancer @UMiamiHealth Congratulations, well deserved indeed!

[Aaron Gerds MD, MS @AaronGerds]

Join us in #Cleveland for @OncLiveSOSS in hematologic malignancies! @ClevelandClinic. @OncLive

[Aaron Gerds MD, MS @AaronGerds]

https://t.co/iqQs1bp1yM my last donation went to Philadelphia and Irvine! Coast-to-coast RBCs!

[Aaron Gerds MD, MS @AaronGerds]

@ASH_hematology What a fantastic discussion today! @ASHClinicalNews #ASH #Fight4Hematology

[Steve Carlson #17 @steve_carlson17]

Friday mood 👊

[Aaron Gerds MD, MS @AaronGerds]

@WashUHematology @WashUDeptMed @mpndoc @ALYoung85 Congratulations 🎉

[Jame Abraham, MD, FACP @jamecancerdoc]

Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis https://t.co/R7iNDlceyi via @clevelandclinic @AaronGerds @CleClinicMD @ClevelandClinic

[Aaron Gerds MD, MS @AaronGerds]

@MikkaelSekeres @TackleCancer @SylvesterCancer @UMiamiHealth Looking good!

[Aaron Gerds MD, MS @AaronGerds]

@Rupayan_MD @MukherzSudipto @jamecancerdoc @CloneTracker @AkritiJain @CCF_IMCHIEFS @medpedshosp @NituKataria @Mud_Fud @VJHemOnc @ASH_hematology Nice job!👍

[HemOnc Today @HemOncToday]

Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to data presented at #ASH24. Healio spoke with @AaronGerds of @caseccc about the findings. #AML #Leukemia
https://t.co/FyFKXttXeK

[Aaron Gerds MD, MS @AaronGerds]

Congrats to Dr. Natalie Wuliji of @fredhutch at #ASH24 for a wonderful plenary discussion! This study examined socioeconomic factors of patients undergoing #bmt for #AML. Honored to be a part of it. @ClevelandClinic @MukherzSudipto

[Aaron Gerds MD, MS @AaronGerds]

Past ASH memories! #ASH24 @ASH_hematology @mpdrc @jamesblachly @MikkaelSekeres @jmikhaelmd

[Aaron Gerds MD, MS @AaronGerds]

@Rupayan_MD @AkritiGJain @CloneTracker @utkarshgoel08 @mushtaqali @JohnHanna @jamecancerdoc @CCF_IMCHIEFS @ccfhemonc Looking good!

[Aaron Gerds MD, MS @AaronGerds]

@joanhowMD @LeivaOrly What a great talk!